Factors associated with adverse reactions to BNT162b2 COVID-19 vaccine reported by hospital workers are unclear. Our aim was to collect all reported adverse events in a cohort of hospital workers and to analyze the factors associated with their presence. We conducted an observational longitudinal study on all hospital workers of our center who received COVID-19 vaccination from 27 December 2020 to 1 September 2021. Information on adverse events was reported telephonically and confirmed through clinical records. Chi-square and t tests as well as multivariate logistic regression models were used. Cluster analysis was designed to explore associations between reactions. A total of 3969 hospital workers were included in the sample. Of the total sample, 182 workers (4.6%) reported adverse events. The most frequent symptoms were general malaise (n = 95), fever (n = 92), arthromyalgia (n = 80), and headache (n = 47). The factors associated with adverse events in adjusted analyses were an antecedent of COVID-19 infection (OR = 2.09, 95% CI: 1.47–2.98), female sex (OR = 1.51, 95% CI: 1.03–2.20), and professional category (OR for physicians = 0.41, 95% CI: 0.21–0.80). We report a low frequency of adverse events in hospital workers after COVID-19 vaccination and no severe reaction. Men and physicians underreported their symptoms. These data should guide future strategies for recording adverse events and future research on COVID-19 vaccination safety.

Keloid is a pathological response of wound healing after a cutaneous lesion in genetically predisposed individuals. 1 Although it is considered a benign disorder, it associates disturbing symptoms, functional impairment and psychological distress, which severely affects patients´ life quality. 2,3 Its current treatments do not often obtain satisfactory responses. In this context, some publications have considered UVA-1 phototherapy a valuable option.A 57-year-old woman attended our dermatologic outpatient clinic referring keloids of 11 years of evolution. The lesions appeared above the incisions of a reduction mammoplasty, distributed on both periareolar and submammary regions. She also complained of pruritus, tenderness and pain, with a pain visual analogue scale (VAS) score of 8 points. They had been previously treated with local excision, resulting in recurrence 4 years later, and with intralesional triamcinolone acetonide, without success. The patient was proposed for low-dose regimen UVA-1 phototherapy (starting dosage of 5 J/ cm 2 , 3 sessions/week, with an increase of 5% per session, reaching a maximum dose of 16.13 J/cm 2 ). After 25 sessions (total accumulated dose of 238.64 J/cm 2 ), we observed softening and flattening of the keloids, which was objectified in reduction of Detroit Keloid Scale from 10 points (severe affectation) to 5 points (moderate affectation), although the improvement affected predominantly to related symptoms. We reported a reduction of pain VAS to 3 points (Figure 1), and the results of Treatment Satisfaction Questionnaire for Medication (TSQM version 1.4) were 90 points in effectiveness, 100 points in side effects, 94 points in convenience and 90 points in overall satisfaction. No adverse events were registered during the treatment. Keloids are a frequent condition which affects between 4.5% and 16% of Hispanic and African-American population. Its formation arises from a disorganized fibroproliferative collagen response which results in excessive production of extracellular matrix. The abnormal activity of keloid fibroblasts, with lower rates of apoptosis, and the

Background The description of the skin reactions produced by the different vaccines against SARS‐CoV‐2 has focused on the symptoms reported by the general population. There are few studies with very different measurement methods focused on healthcare workers. Methods A longitudinal observational study was conducted on all the healthcare workers from the Hospital Universitario San Cecilio that received vaccination against COVID‐19 with BNT162b2. The recruitment period was from December 2020 to September 2021. The recommended regimen was double, with a minimum interval of 21 days between doses. All dermatological reactions reported as adverse effects of the vaccine were evaluated by the Staff of the Dermatology Unit of our center. Results A total of 3969 healthcare workers of our center were followed. Only 0.7% of them reported dermatological adverse reactions. The most frequently reported reactions were morbilliform rash and COVID arm. In the multivariate analysis, the vaccination regimen (one dose) and the history of COVID‐19 infection remained the main factors associated with the report of dermatological adverse reactions. Conclusion The rate of dermatological adverse reactions after vaccination with BNT162b2 (Pfizer‐BioNTech) is extraordinarily low. No patient required hospitalization, which supports the safety of this vaccination in a population of healthcare workers.

No abstract

No abstract